How many days can a single box of Quizartinib be taken?

Quizartinib (Quizartinib) is a selective FLT3 inhibitor, a targeted drug designed specifically for FLT3-ITD mutant acute myeloid leukemia (AML). It has been approved in multiple countries for induction, consolidation and maintenance therapy in patients with newly diagnosed FLT3-ITD-positive AML. The dosage is relatively standardized and adjusted with the treatment stage, so the number of days a single box of medicine can be used mainly depends on the specifications used and the specific treatment plan.

The two common specifications currently are17.7mg/tablet (28 tablets per box) and 26.5mg/tablet (56 tablets per box). During the standard induction and consolidation treatment phases, the recommended dose is 35.4 mg taken orally daily, approximately two 17.7 mg tablets. It is not affected by food when taken and can be taken at a fixed time every day to maintain the stability of blood concentration. In induction therapy, the administration of quizartinib began on day 8 of chemotherapy and continued until day 21 for a 14-day period. During the consolidation phase, dosing began on day 6 of each cycle and continued until day 19, also lasting 14 days. The dosing cycle of both phases is a 28-day course of treatment, of which the actual dosing time of Quizartinib is half a cycle, that is, 14 days per dosing.

Based on the specifications, if the patient takes the recommended dose of 35.4mg daily and uses the 17.7mg tablet size, he needs to take two tablets a day. A box of 28 tablets can be used for 14 days, which is suitable for a complete induction or consolidation phase of drug supply. If you use 26.5mg tablets, you need to take one tablet of 26.5mg and half a tablet of 17.7mg every day. It is impossible to complete the entire dose with a single specification, so it is usually necessary to use two specifications together. In actual clinical use, doctors will combine dosages and accurately distribute drugs according to the patient's specific conditions.

In addition to induction and consolidation therapy, the recommended dose of Quizartinib during the maintenance treatment phase usually starts from 26.5 mg per day, and may be increased to 53 mg per day (two 26.5 mg tablets) depending on whether the patient's QTc interval is prolonged. Dosing at this stage is continuous daily without intermittent use, so the frequency of use is higher and the number of days for a single box of medication will be reduced accordingly.

Reference materials:https://go.drugbank.com/drugs/DB12874